Ethoheptazine

Source: Wikipedia, the free encyclopedia.
Ethoheptazine
Clinical data
Trade namesEquagesic
Other namesZactane
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
Identifiers
  • Ethyl 1-methyl-4-phenylazepane-4-carboxylate
JSmol)
  • O=C(OCC)C2(c1ccccc1)CCN(C)CCC2
  • InChI=1S/C16H23NO2/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16/h4-6,8-9H,3,7,10-13H2,1-2H3 checkY
  • Key:WGJHHMKQBWSQIY-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ethoheptazine[1] (trade name Zactane) is an opioid analgesic from the phenazepane family. It was invented in the 1950s[2] and is a ring expanded analogue of pethidine.[3]

Ethoheptazine produces similar effects to other opioids, including

Equagesic, which is used for the treatment of conditions where both pain and anxiety are present.[5] It was also investigated for use as an antitussive.[6]

It is no longer prescribed, as it is no longer FDA approved, and not available for United States' Pharmacy Processing. Revocation of FDA Approved Medications Status stems from a combination of efficacy vs. toxicity, and the more-varied and historically safer Benzodiazepines Class. Only reversal of the FDA's decision, allows removing the drug from the CSD. Ethoheptazine is not listed as a controlled substance under the Controlled Substances Act, 1970 in the United States.[7] The controlled status (Schedule IV) of Equagesic was due to the meprobamate content.[8][7] Regulation elsewhere varies.

References

  1. ^ ES 310184, "Procedure for the preparation of a new derivative of pirazolidine-hexametilenimina with therapeutic properties." 
  2. S2CID 32299049
    .
  3. .
  4. .
  5. .
  6. .
  7. ^ a b "Conversion Factors for Controlled Substances". Diversion Control Division. Drug Enforcement Agency, U.S. Department of Justice. Archived from the original on 2016-03-02. Retrieved 2016-02-27.
  8. ^ PDR 1978, pp 1618